peptidefix

Peptides / Thymosin alpha-1 / Australia

Thymosin alpha-1 in Australia

Legal status, what it is, and the listed suppliers in Australia that list it.

Legal status in Australia

Not an approved medicine. Not listed by name in the Poisons Standard (June 2026).

As understood at 2026-09-22. Verify with the TGA.

What Thymosin alpha-1 is

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymus tissue, the gland where T cells mature. The synthetic form is called thymalfasin. It has been through a large clinical programme as an immune modulator, mostly outside the UK, US and Australia, and is not an approved medicine in any of the three.

Full Thymosin alpha-1 page: targets and research →

Listed suppliers in Australia

3 of the 10 suppliers we list in Australia list Thymosin alpha-1. Listed, not endorsed: each row is the supplier’s own stated terms.

Aussie Peptides Australia Research use only. Statements have not been evaluated by the TGA. We do not ship internationally at this time. Australian Peptide Site Australia Intended for laboratory and scientific research use only. Global Peptides Australia Unmodified peptides are sold for research use only.

Clinical Research

The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Wu J, Pei F, Zhou L, et al. (2025). BMJ. human 1,106 adults with sepsis across 22 centres in China; phase 3, double-blind, placebo-controlled
A Pilot Trial of Thymalfasin (Thymosin-alpha-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection
Shehadeh F, Benitez G, Mylona EK, et al. (2023). The Journal of Infectious Diseases. human 49 hospitalised patients with COVID-19, low oxygen levels and low lymphocyte counts; open-label, randomised against standard care
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression
Soeroto AY, Suryadinata H, Yanto TA, Hariyanto TI (2023). Inflammopharmacology. meta-analysis n/a (pooled analysis of 8 studies in moderate to critical COVID-19)
Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
Cao A, Feng F, Zhou X (2024). Journal of the College of Physicians and Surgeons Pakistan. meta-analysis n/a (39 randomised trials, 3,329 patients with acute exacerbation of COPD)